Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas). The mechanism of TMZ-induced glioma cell death is unknown. Here, we show that malignant glioma cells undergo apoptosis following treatment with the methylating agents N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) and TMZ. Cell death determined by colony formation and apoptosis following methylation is greatly stimulated by p53. MeGtriggered apoptosis requires Fas/CD95/Apo-1 receptor activation in p53 non-mutated glioma cells, whereas in p53 mutated gliomas the same DNA lesion triggers the mitochondrial apoptotic pathway. This occurs less effectively via Bcl-2 degradation and caspase-9, -2, -7 and -3 activation. O 6 MeG-triggered apoptosis in gliomas is a late response (occurring >120 h after treatment) that requires extensive cell proliferation. Stimulation of cell cycle progression by the Pasteurella multocida toxin promoted apoptosis whereas serum starvation attenuated it. O 6 MeGinduced apoptosis in glioma cells was preceded by the formation of DNA double-strand breaks (DSBs), as measured by cH2AX formation. Glioma cells mutated in DNA-PK cs , which is involved in non-homologous endjoining, were more sensitive to TMZ-induced apoptosis, supporting the involvement of DSBs as a downstream apoptosis triggering lesion. Overall, the data demonstrate that cell death induced by TMZ in gliomas is due to apoptosis and that determinants of sensitivity of gliomas to TMZ are MGMT, p53, proliferation rate and DSB repair.
Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas). The mechanism of TMZ-induced glioma cell death is unknown. Here, we show that malignant glioma cells undergo apoptosis following treatment with the methylating agents N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) and TMZ. Cell death determined by colony formation and apoptosis following methylation is greatly stimulated by p53. Transfection experiments with O MeGtriggered apoptosis requires Fas/CD95/Apo-1 receptor activation in p53 non-mutated glioma cells, whereas in p53 mutated gliomas the same DNA lesion triggers the mitochondrial apoptotic pathway. This occurs less effectively via Bcl-2 degradation and caspase-9, -2, -7 and -3 activation. O 6 MeG-triggered apoptosis in gliomas is a late response (occurring >120 h after treatment) that requires extensive cell proliferation. Stimulation of cell cycle progression by the Pasteurella multocida toxin promoted apoptosis whereas serum starvation attenuated it. O Introduction During the last years, anticancer drugs with methylating properties (such as temozolomide [TMZ] , procarbazine, dacarbazine, streptozotocine) have received much attention, notably in the therapy of malignant gliomas. These drugs target DNA, inducing about a dozen DNA methylation products (Beranek, 1990) . Studies with O 6 -methylguanine-DNA methyltransferase (MGMT)-deficient cells (Sklar and Strauss, 1981; Scudiero et al., 1984; Preuss et al., 1996) and MGMT-transfected isogenic cell lines (Kaina et al., 1991) unequivocally revealed that one of the lesions, the minor alkylation product O 6 -methylguanine (O 6 MeG), is a most potent killing lesion. It acts as a powerful trigger of apoptosis (Kaina et al., 1997; Tominaga et al., 1997; Meikrantz et al., 1998) . In the cell killing process driven by O 6 MeG mismatch repair (MMR) is essentially involved (Kat et al., 1993; Kaina et al., 1997; Hickman and Samson, 1999; Pepponi et al., 2003) . If O 6 MeG is repaired, cells are either resistant to O 6 MeG-triggered apoptosis or die because of harmful N-alkylation lesions such as 3-methyladenine, 3-methylguanine and apurinic sites that have arisen from N-methylpurine hydrolysis (Lindahl, 2000) . The contribution of O 6 MeG to cell death depends on the ratio of O 6 MeG to N-alkylations in the DNA, the capacity of the cell to repair O 6 MeG and the rate of repair of N-alkylations (Kaina et al., 1997 MeG is not only an apoptotic but also a genotoxic (for a review see Margison and Santibanez-Koref, 2002) , tumour-initiating (Dumenco et al., 1993; Becker et al., 1996) and tumour-converting (Becker et al., 2003) lesion. Repair of O 6 MeG is accomplished by the suicide repair protein MGMT via direct methyl group transfer from the oxygen in guanine to a cystein residue (Cys145) in the MGMT molecule. Guanine in DNA is thereby restored and MGMT gets inactivated (for a review see Pegg, 2000) . Because of the stochiometry of the reaction the repair capacity strictly depends on the amount of pre-existing MGMT molecules in the cell. The level of MGMT in tumours is highly variable. Quite low amounts are expressed in brain tumours (Chen et al., 1992; Preuss et al., 1995; Silber et al., 1999; Bobola et al., 2001) , presumably due to MGMT promoter methylation (Esteller et al., 1999 (Esteller et al., , 2001 . MGMT expression level (Chen et al., 1999; Anda et al., 2003) and, as recently shown, MGMT promoter methylation (Esteller et al., 2000; Hegi et al., 2004 Hegi et al., , 2005 Paz et al., 2004) were predictive for the clinical response to chemotherapy, stressing the critical role of MGMT in determining alkylating drug resistance (for a review see Gerson, 2004) . Brain tumours, notably malignant gliomas, are highly therapy-refractory tumours. Therapy of gliomas includes tumour resection, followed by radiotherapy and chemotherapy that usually involves O 6 -alkylating agents. The methylating agent TMZ was shown to prolong survival of patients when administered during and after radiotherapy as part of the first-line treatment (Stupp et al., 2005) .
Despite the usefulness of O 6 -methylating agents in glioma therapy, the median survival times of patients suffering from the most severe form glioblastoma multiforme are still remarkably low (12-14 months). Obviously, there is an urgent need for improving glioma therapy. One goal that needs to be reached in achieving this would be to improve our knowledge on the mechanism of alkylating agent-induced death in glioma cells. Whereas the mechanism of apoptosis induced by O 6 -methylating agents has been elucidated in great detail in various experimental systems such as rodent cell lines (Ochs and Kaina, 2000) , lymphoblastoid cells (Dunkern et al., 2003; Hickman and Samson, 2004) and peripheral human lymphocytes (Roos et al., 2004) , it remains enigmatic in malignant gliomas and other tumour types. Thus, for human glioma cells, TMZ was reported to induce either a p53-associated G2/M arrest followed by senescence or p53-independent mitotic catastrophe (Hirose et al., 2001) . In another study, TMZ was proposed to induce autophagy but failed to induce apoptosis in malignant glioma cells (Kanzawa et al., 2004) , whereas glioma cells grown as spheriods have been shown to be able to undergo apoptosis following alkylating agent treatment (Gunther et al., 2003) . These conflicting data prompted us to study the mechanism of glioma cell death upon treatment with methylating agents in detail. Here, we show that human malignant glioma cells undergo apoptosis dose and time dependently upon methylating agent treatment for which the specific DNA lesion O 6 MeG is the decisive trigger. We also demonstrate that MGMT protects against TMZ-induced apoptosis in gliomas. O 6 MeG-triggered apoptosis in glioma cells is dependent on the p53 status that determines whether cells undergo death receptor or mitochondrial apoptosis. Furthermore, we show the importance of DNA doublestrand break (DSB) formation and cell proliferation in O 6 MeG-triggered apoptosis of glioma cells. Clinical implications will also be discussed.
Results

Methylating agents reduce colony formation of glioma cells
The cytotoxic effect of the powerful O 6 -methylating agent N-methyl-N 0 -nitro-N-nitrosoguanidine (MNNG) on U87MG (p53wt) and U138MG (p53mt) glioma cells was examined in colony-forming survival assays. As shown in Figure 1 , U87MG (p53wt) cells are clearly more sensitive to the killing effect of MNNG than U138MG (p53mt) cells.
Induction of apoptosis following MNNG or TMZ treatment and influence of the p53 status on apoptosis To show that the killing effect observed after methylating agent treatment in p53 wild-type and p53 mutant glioma cells is related to the induction of apoptosis, the apoptotic response was measured as a function of drug concentration. MNNG and TMZ induced apoptosis in a concentration dependent manner (Figure 2a and b) . Importantly, the onset of apoptosis was observed at very late time points in cultures that were growing exponentially throughout the whole time of the experiment, starting at 96 h after MNNG treatment and increasing in frequency up to 144 h ( Figure 2f ). p53 wildtype glioma cells (U87MG) were clearly more sensitive than p53 mutated cells (U138MG) to the induction of apoptosis by MNNG and TMZ through the whole concentration range tested (Figure 2a and b), indicating p53 to be involved in triggering apoptosis upon methylation. To substantiate the role of p53 in methylating agent-induced apoptosis, p53 was inhibited in both cell lines using the specific inhibitor pifithrin-a. In U87MG (p53wt) cells, inhibition of p53 caused a significant decrease in the apoptotic response following MNNG and TMZ treatment whereas pifithrin-a had no effect in p53 mutant cells (Figure 2c and d). To determine whether MNNG can cause the stabilization and nuclear localization of p53 in glioma cells, we treated U87MG (Figure 2e ), corresponding to the induction of apoptosis (Figure 2f ).
In time course experiments, an extra p53 mutant glioma cell line was included, namely LN308 (p53mt). Both p53 mutant cell lines, U138MG and LN308, showed a clearly lower apoptotic response than the p53 wild-type cell line U87MG (Figure 2f ). An additional experiment supporting the influence of p53 on the induction of apoptosis was performed by using U87MG glioma cells stably transfected with siRNA targeted to p53 (Figure 2g ). In these cells, p53 was clearly less expressed than in the parental line (Figure 2g , inset). With a clinically relevant concentration of TMZ (100 mM), the knockdown of p53 in U87MG cells significantly reduced apoptosis. Collectively, the data demonstrate that, upon methylation, p53 is involved in determining the cytotoxic and apoptotic response of glioma cells.
Influence of MGMT on O 6 MeG-triggered apoptosis The question of whether O 6 MeG lesions are responsible for apoptosis upon DNA methylation in glioma cells had to be answered next. To this end, U87MG (p53wt) and U138MG (p53mt) cells were stably transfected with MGMT in order to compare the apoptotic response in cells not expressing and expressing MGMT (see Figure 3a and b for protein levels). Whereas U87MG (p53wt) and U138MG (p53mt) cells showed no MGMT activity, U87MGMT and U138MGMT showed MGMT activities of B600 and B800 fmol/mg protein, respectively (Figure 3c and d). MGMT overexpression decreased apoptosis in U87MG (p53wt) and U138MG (p53mt) cells by approximately 90% after MNNG (1 or 5 mM) treatment (Figure 3e and f). When inhibiting MGMT in U87MG and U138MG cells that were stably transfected with MGMT (designated as U87MGMT and U138MGMT respectively) with O 6 -benzylguanine (O 6 BG), the cells showed a dramatic increase in apoptosis upon treatment with MNNG ( Figure 3e and f). As MGMT specifically repairs O 6 -methylations (the minor lesion O 4 -methylthymine can be neglected), the strong apoptotic response in MGMT deficient gliomas and the inhibition of apoptosis in MGMT overexpressing glioma cells clearly show that at least 90% of the apoptotic signalling upon TMZ treatment originates from O 6 MeG lesions.
Replication dependence of O 6 MeG-triggered apoptosis in glioma cells
The late onset of apoptosis upon pulse methylation of proliferating cells indicates that apoptosis occurs not in the treatment but in one of the post-treatment cell cycles. To elucidate the dependence of apoptosis on cell cycle progression following O 6 MeG induction, two strategies were employed: (1) inhibiting cells from progressing through the cell cycle and (2) by pushing cells to divide faster. Firstly, slowing or stopping the proliferation of U87MG (p53wt) cells by serum starvation provoked the apoptotic response to decrease by approximately 55% (Figure 4a ). Secondly, we proved the opposite argument that forcing glioma cells to progress through the cell cycle will give rise to a stronger apoptotic response. For this reason, U87MG (p53wt) cells were treated with the powerful mitogen PMT, thereby increasing the proliferation rate of the cells (Figure 4b , left panel). Treatment with PMT leads to more than double the apoptotic frequency ( Figure 4b , right panel). Thus, manipulation of cell cycle progression after methylating agent exposure demonstrates that glioma cells require cellular proliferation in order for O 6 MeG to be able to trigger the apoptotic response. It is obvious that extensive proliferation stimulates the apoptotic response provoked by O 6 MeG lesions.
Importance of the formation of DNA DSBs on apoptosis following O 6 -methylguanine induction It has been shown previously that unrepaired O 6 MeG lesions give rise to DSBs (Ochs and Kaina, 2000; Roos et al., 2004) . It has also been shown that 'clean' DSBs are a powerful trigger of apoptosis (Lips and Kaina, 2001 ). To substantiate a role of DSBs in methylating agent-induced apoptosis for glioma cells, the formation of DSBs were assayed following O 6 -methylating agent treatment. In U87MG (p53wt) cells, MNNG treatment led to the formation of DSBs as visualized by an increase in the presence of phosphorylated H2AX (Figure 5a ). This was again observed at late time points (48-96 h), preceding the onset of apoptosis. Next, we determined whether methylation-induced DSBs are also related to apoptosis in glioma cells. To this end, MO59K glioma DNA-PK wild-type and MO59J glioma DNA-PK-deficient cells were compared following MNNG ( Figure 5b ) and TMZ (Figure 5c ) treatment. To deplete MGMT completely, cells were pretreated with O 6 BG. In both cases, the DNA-PK-deficient cells were more sensitive to apoptosis induction than wild-type cells (Figure 5b and c) . As DNA-PK is involved in the repair of DSBs by non-homologous end joining (NHEJ), these data support the hypothesis that in glioma cells DSBs are critically involved in O 6 MeG-triggered apoptosis. It has been suggested that inhibition of transcription may trigger apoptosis (Ljungman and Zhang, 1996) . Therefore, we checked the level of transcriptional inhibition by TMZ. As shown in Figure 5d , TMZ (100 mM) did not attenuate the rate of transcription as measured immediately (2 h) and late (48 h) after treatment. It rather stimulated transcription at late postexposure times in U87MG (p53wt) cells. Therefore, transcriptional inhibition can be excluded as a mechanism of TMZ-induced apoptosis.
Death receptor signalling in O 6
MeG-triggered apoptosis in glioma cells To determine whether glioma cells utilize the death receptor mediated apoptotic pathway triggered by O 6 MeG, the expression of the Fas receptor (Fas, CD95, Apo-1) was assayed. In membrane extracts of U87MG (p53wt) cells, a clear induction of Fas was observed following MNNG treatment (Figure 6a ). This increase in Fas protein was again observed at late times (Figure 6a ). U138MG (p53mt) cells did not express Fas (Figure 6a ). By using a specific antagonizing antibody against Fas, thereby inactivating receptor signalling, a decrease in TMZ-induced apoptosis of approximately 55% was observed in U87MG (p53wt) cells, whereas no MeG triggers the mitochondrial apoptotic pathway characterized by a decline in Bcl-2 protein level (Ochs and Kaina, 2000) . Therefore, we followed the hypothesis that in p53 mutant glioma cells the mitochondrial pathway is activated in response to O 6 MeG lesions. Indeed, as shown in Figure 7a , after MNNG treatment U138MG (p53mt) cells exhibit the characteristic decline in Bcl-2. This was not observed in p53wt glioma cells (data not shown). Bcl-2 decline was accompanied by caspase-9 activation as well as the activation of the executive caspases-3 and -7 (Figure 7b-d) . Also caspase-2 became activated (Figure 7e ) whereas no caspase-8 activation was observed in U138MG (p53mt) cells (Figure 7f ). These data are in agreement with the view that in p53-mutated glioma cells, O 6 MeG triggers the mitochondrial-mediated apoptotic pathway whereas in p53 wild-type cells the same lesion triggers the death receptor pathway.
Caspase inhibition attenuates O
6 MeG-triggered apoptosis The activation of multiple caspases, as shown in Figure 7 , prompted us to determine whether apoptosis MeG in glioma cells is dependent on cellular proliferation (Figure 4 ) and occurs at very late times following exposure (Figure 2f) . Therefore, an inhibitor approach might exhibit only low effectiveness particularly if the inhibitor is unstable and the substrate gets re-synthesized. In this approach, we applied the broad-spectrum caspase inhibitor Boc-D-fmk. In U87MG (p53wt) and U138MG (p53mt) cells, the caspase inhibitor was able to decrease the apoptotic response by approximately 30% (Figure 8 ). This inhibition of apoptosis was statistically significant in both cell lines (Po0.001). Together with the demonstration of caspase activation (Figure 7 and data not shown), the attenuation of apoptosis by Boc-D-fmk demonstrates that caspases are involved in O 6 MeGtriggered apoptosis in glioma cells.
Discussion
Patients suffering from malignant glioma, in particular glioblastoma multiforme, have a very poor prognosis. Standard therapy today, in addition to surgery and radiotherapy, includes treatment with alkylating agents, specifically TMZ and the chloroethylating drugs carmustine and nimustine. Currently and in the future, the use of TMZ and presumably also other methylating drugs will become more dominant than chloroethylating agents because of less severe side effects. The common use of O 6 -methylating agents in glioma therapy provokes the question of how these agents exert their killing effects and, based on the data obtained, is it possible to improve glioma chemotherapy? As the molecular action of O 6 -alkylating agents in gliomas (and other tumour types) is largely unknown, this study was aimed at elucidating the mode of death of glioma cells upon treatment with O 6 -methylating agents.
Here, we show that glioma cells undergo apoptosis following treatment with TMZ or MNNG (that acts in the same way as TMZ upon decomposition into reactive carbenium ions). Apoptosis in glioma cell lines is a very late response, occurring no earlier than 4 days after pulse treatment of exponentially growing cultures. This late response might explain the failure of detection of apoptosis in previous studies with glioma cells. Modulation of MGMT activity by pharmacological inhibition with O 6 BG (Dolan et al., 1990) or MGMT cDNA transfection (Kaina et al., 1991) 
MeG is the major proapoptotic DNA lesion in malignant glioma cells upon O 6 -methylating agent treatment. As MGMT strongly protects against O 6 MeG-triggered apoptosis, the data also confirm that MGMT is a decisive determinant of glioma resistance to O 6 -methylating agents.
An intriguing observation was that p53 wild-typeexpressing glioma cells were more sensitive than their p53 mutant counterparts, and that pharmacological inhibition of p53 by pifithrin-a or knockdown of p53 by siRNA provoked O 6 -methylating agent resistance. This clearly illustrates that p53 is involved in O 6 MeGtriggered apoptosis in gliomas. As both p53 wild-type and p53 mutant glioma cells were able to undergo apoptosis in response to TMZ, we conclude that p53 is not absolutely required, but stimulates the apoptotic process. The p53 gene is often mutated in human cancers. Secondary glioblastomas that develop from grade II or III astrocytomas exhibit a p53 mutation frequency of 65%, whereas primary glioblastomas exhibit a quite low p53 mutation frequency of 10%. As p53 wild-type exerted a strong positive effect on O 6 -methylating agent sensitivity, p53 must be considered as a predictive factor in glioma therapy. As p53 mutant glioma cells are more resistant to TMZ, the data also implicate that p53-mutated tumour cells may be selected after treatment with TMZ or other methylating agents, resulting in recurrent gliomas that would not respond to the same treatment.
How does p53 stimulate apoptosis triggered by O 6 MeG in glioma cells? In p53 wild-type, but not in p53 mutant glioma cells, O 6 -methylating agents provoked the induction of Fas (CD95, Apo-1) receptor expression and activation of the Fas-dependent apoptotic pathway (Figure 6 ), including activation of caspase-8 (data not shown). Transfection with DN-FADD attenuated apoptosis, which suggests that Fas is involved in O 6 MeG-triggered apoptosis in p53 wild-type glioma cells. p53 is a transcriptional activator of Fas (Muller et al., 1998; Pohl et al., 1999) , which explains its upregulation upon treatment of glioma cells with O 6 -methylating agents. Interestingly, in p53 mutant glioma cells Fas and caspase-8 were not induced, whereas Bcl-2 declined and caspase-9 and -3 were activated in response to MNNG. The decline of Bcl-2 is a hallmark of O 6 MeG-triggered apoptosis in p53-mutated cells (Ochs and Kaina, 2000) . The data therefore show that in p53 mutant glioma cells, O 6 -methylating agents are able to trigger the intrinsic mitochondrial apoptotic pathway. It is important to note that the mitochondrial pathway is MeG-triggered apoptosis. U87MG (p53wt) and U138MG (p53mt) cells were treated with 5 mM MNNG and 5 mM O 6 BG in the presence and absence of the broad-spectrum caspase inhibitor Boc-D-fmk. Boc-D-fmk (50 mM) was added 72 h after MNNG treatment, before the onset of apoptosis, and then 25 mM every 24 h until samples were stopped. Data are the mean of three experiments7s.d. less efficiently evoked than the death receptor pathway. Consequently, at equimolar doses of TMZ p53 wildtype glioma cells deficient in MGMT exhibited a much greater response than p53 mutant cells. In both p53 wild-type and mutant glioma cells, transfection with MGMT blocked apoptosis almost to completion. This shows that O 6 MeG is the main trigger of apoptosis irrespective of the p53 status of cells. Given the data, p53 can be considered as a decision maker of whether the same DNA lesion, O 6 MeG, triggers the death receptor or the mitochondrial apoptotic pathway (see Figure 9 ). The potency of the lesion to trigger, in the absence of p53, the mitochondrial pathway is, however, clearly lower than to trigger the death receptor pathway.
How does p53 get activated in response to O 6 MeG? The current model supported by a bulk of data is outlined in Figure 9 . It proposes that O 6 MeG does not trigger apoptosis on its own. It rather becomes converted into a critical downstream lesion that is supposed to be DSBs. This occurs, according to a reasonable model, by mispairing of O 6 MeG lesions with thymine, which in turn is processed by MutSa-dependant mismatch repair provoking a futile MMR cycle (Karran and Bignami, 1994; Hampson et al., 1997) . Secondary lesions will be formed that cause replication interference in the subsequent DNA replication cycle leading ultimately to DSBs (Ochs and Kaina, 2000) . As shown recently, the glioma cells used in this study express similar levels of the MMR proteins MSH2 and MSH6 (Hermisson et al., 2006) . They show DSB formation, as demonstrated by gH2AX induction that preceded apoptosis. A key repair pathway for DSBs is NHEJ that involves DNA-PKcs. Indeed, apoptosis induced by MNNG and TMZ was enhanced in DNAPKcs mutated glioma cells, which supports the view that DSBs are formed in response to O 6 MeG, contributing to apoptosis. The apoptotic response may occur by stabilization of p53 via the ATM/ATR-Chk1 pathway (O'Connell and Cimprich, 2005) . Interestingly, however, cells deficient in ATM are hypersensitive to methylating agents (Debiak et al., 2004) . Similarly, cells lacking XRCC2 are hypersensitive to TMZ and MNNG (Tsaryk et al., 2005) . This supports a role of ATM and XRCC2 in the repair of DSBs originating from O 6 MeG lesions rather than apoptotic signalling. The apoptotic response of gliomas upon TMZ treatment can also be provoked by a p53-independent activity that degrades Bcl-2. The signalling involved in the Bcl-2-driven pathway still remains enigmatic.
The model described above implicates DNA replication and cell proliferation as essential elements in O 6 MeG-triggered apoptosis in glioma cells. This is indeed the case, as substantiated by experiments in which proliferation was either blocked or stimulated. Inhibition of glioma cell proliferation clearly reduced the frequency of apoptosis upon O 6 -methylating agent treatment, whereas stimulation of proliferation by treatment with the powerful mitogen, Pasteurella multocida toxin (PMT) (Orth et al., 2003) significantly enhanced apoptosis. Therefore, proliferation rate appears to be an important predictive factor in O 6 MeGdriven apoptosis in gliomas and very likely also in other tumour types. These data also show that any proliferation blocking treatment applied together or after TMZ might attenuate the therapeutic effect of TMZ. We should note that the concentration range of the methylating agents used throughout this work was relatively low, allowing full recovery and propagation of cells. For TMZ, the concentration range corresponds to serum levels achieved during treatment, namely 100 mM (Hammond et al., 2004) . In summary, the data reported here show that glioma cells die after methylating agent treatment owing to the induction of apoptosis. This apoptotic response is primarily due to O Alkylating agent-induced apoptosis in glioma cells WP Roos et al the mitochondrial pathway. The modulation of cell proliferation and DSB repair had a significant impact on O 6 MeG-triggered apoptosis. The data obtained suggest that predictive markers of TMZ sensitivity of gliomas are MGMT activity, proliferation rate, p53 status and the efficiency of DSB repair.
Materials and methods
Cell lines and culture conditions
The glioma cell lines U87MG, U138MG, LN-308, M059K and M059J were used in this study. U87MG is p53 wild-type whereas U138MG and LN-308 are p53 mutant (Wischhusen et al., 2003) . M059K is DNA-PK wild type and M059J lack the p350 component of DNA-PK (Allalunis-Turner et al., 1995). All cell lines were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.
Clonogenic survival assays
Colony-forming assays were performed as previously described (Roos et al., 2000) . Shortly, U87MG (p53wt) and U138MG (p53mt) glioma cells, growing in log phase were used. Cells were seeded in triplicate at appropriate cell numbers in 60 mm Petri dishes to yield approximately 100 surviving colonies after MNNG treatment. Cells were allowed to attach and then exposed to increasing concentrations of MNNG. After 2-3 weeks colonies were fixed (in acetic acid:methanol:H 2 O 1:1:8), stained (in 0.01% amido black) and colonies containing 50-100 cells were counted. The surviving fraction was plotted on a log scale and fitted to the linear-quadratic equation.
Apoptosis determined by flow cytometry
The apoptotic response after genotoxic drug treatment was measured using the flow cytometric method of sub-G1 determination. Treated and untreated cells were harvested, washed once with phosphate-buffered saline (PBS) and fixed in 70% ethanol. Ethanol-fixed cells were stained with propidium iodide (16.5 mg/ml) in PBS after RNase (0.03 mg/ml) digestion. Samples were analysed in a FACS Calibur (Becton Dickinson, Heidelberg, Germany). For each sample 10 000 cells were analysed. The number of apoptotic cells was calculated using the Cell Quest software (Heidelberg, Germany).
Drugs and drug treatment MNNG (Sigma, Munich, Germany) stock solution was prepared by dissolving MNNG in dimethyl sulfoxide and then diluting it with sterile dH 2 O. TMZ (Schering-Plough, Kenilworth, NJ, USA) stocks were prepared by dissolving the drug in ethanol and diluting it with sterile dH 2 O. Stock solutions were filtered, aliquoted and stored at À801C. Glioma cell lines were treated with increasing concentrations of either MNNG or TMZ and then harvested after 144 h to determine apoptosis. For the time responses, the glioma cells were treated with MNNG and then harvested at the appropriated times. The p53 inhibitor pifithrin-a, which reversibly blocks p53 dependent transcriptional activation (Komarova and Gudkov, 2000) , was added 72 h after treatment with either 10 mM MNNG or 100 mM TMZ and apoptosis was determined at time point 144 h. The specific MGMT inhibitor O 6 BG (Pegg et al., 1993) was added 1 h before MNNG treatment at a concentration of 10 mM. The powerful mitogen, Pasteurella multocida toxin (PMT wt ), and the inactive mutant PMT C1165S (Orth et al., 2003) were kept in a 1.1 mg/ml stock solution (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 2.5 mM CaCl 2 ) at À201C and used at a concentration of 10 ng/ml (the mitogen was a kind gift of Dr Klaus Aktories, Freiburg). Caspases were inhibited using the broad-spectrum caspase inhibitor Boc-D-FMK (Calbiochem, San Diego, USA). After treating U87MG p53 wild-type and U138MG p53 mutant glioma cells with 5 mM MNNG and O 6 BG, caspases were inhibited with adding 50 mM Boc-D-FMK 72 h after methylation and then 25 mM every 24 h until the samples were harvested at 144 h.
Preparation of protein extracts
Fractionated cell extracts Cell pellets of treated and untreated samples were suspended in fractionation buffer A (10 mM HEPES-KOH, pH 7.4, 0.1 mM ethylene diaminetetraacetic acid (EDTA), 1 mM ethylene glycol-bis (b-aminoethyl ether), 250 mM sucrose, 1 mM Na 3 VO 4 , 0.5 mM phenylmethylsulfonyl fluoride (PMSF) and 10 mM dithiothreitol (DTT)). The cells were lysed by freeze/thaw/vortexing. The lysate was then centrifuged at 10 000 r.p.m. for 10 min and the supernatant containing the cytoplasmic proteins was isolated. The pellet, containing the nuclei, organelles and membranes, were then suspended in fractionation buffer B (20 mM Tris, 1 mM EDTA, 1 mM b-mercaptoethanol, 5% glycerine, 1 mM Na 3 VO 4 , 0.5 mM PMSF, 10 mM DTT, pH 8.5). This suspension was homogenized by sonication. After centrifugation at 10 000 r.p.m. for 10 min the supernatant contains the nuclear proteins and the pellet the membrane fragments. This membrane pellet was suspended in fractionation buffer B containing 1% Triton X-100. The protein concentration was determined by the method of Bradford (Bradford, 1976) .
Cell extracts for MGMT activity assay Cells were harvested and homogenized by sonication in buffer containing 20 mM Tris-HCl, pH 8.5, 1 mM EDTA, 1 mM b-mercaptoethanol, 5% glycerol and the protease inhibitor PMSF (0.1 mM). The extract was centrifuged at 10 000 r.p.m. (10 min) in the cold in order to remove debris and the supernatant was snap-frozen in aliquots using liquid nitrogen and stored at À801C until use.
Western blot analysis
The method used here is based on the method described by Renart et al. (1979) . Protein (30 mg) of cell extracts was separated in a 12% SDS polyacrylamide gel. Thereafter, proteins were blotted onto a nitrocellulose transfer membrane (Protran; Schleicher & Schuell, Dassel, Germany) for 3 h. Membranes were blocked for 2 h at room temperature in 5% (wt/vol) fat-free milk powder in TBS containing 0.1% Tween 20, incubated overnight at 41C with the primary antibody (1:500-1000 dilution), washed three times with 0.1% Tween 20 in TBS, and incubated for 2 h with a horseradish peroxidasecoupled secondary antibody 1:3000 (Amersham Biosciences AB, Uppsala, Sweden). Antibodies used were anti-p53 (BD PharMingen, San Diego, USA), anti-Fas (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-Bcl-2 and anti-Bax (Santa Cruz Biotechnology Inc.), anti-GAPDH (Ambion Inc.), anti-MGMT (Chemicon International Inc.), anti-ERK2 (Santa Cruz Biotechnology Inc.), anti-gH2AX (Upstate, Dundee, Scotland), anti-caspase-8 (Cell Signalling, Danvers, USA), anti-caspase-9 (Cell Signalling), anti-caspase-2 (Neomarkers, Fremont, USA), anti-caspase-7 (Cell signalling) and anti-caspase-3 (Cell Signalling). After final washing with 0.1% Tween 20 in TBS (3 times for 10 min each) blots were developed by using a chemiluminescence detection system (Amersham Biosciences AB).
